L Ceniceros1, J Aristu2, E Castañón1, C Rolfo3, J Legaspi1, A Olarte2, G Valtueña2, M Moreno2, I Gil-Bazo4. 1. Department of Oncology, Clínica Universidad de Navarra, Pío XII 36, 31008, Pamplona, Spain. 2. Department of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain. 3. Oncology Department and Multidisciplinary Oncology Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium. 4. Department of Oncology, Clínica Universidad de Navarra, Pío XII 36, 31008, Pamplona, Spain. igbazo@unav.es.
Abstract
INTRODUCTION: Lung cancer is the most frequent neoplasm in humans. Surgery is considered the best therapeutic approach for stage I non-small lung cell cancer (NSCLC). However, a remarkable amount of patients are considered as inoperable. Stereotactic body radiotherapy (SBRT) has risen as an option for those patients, rendering excellent results in quality of life and survival. MATERIALS AND METHODS: We analyzed clinical studies published between 2002 and 2015 which included SBRT as a treatment modality. Our own clinical series was analyzed as well. The patterns of failure following SBRT were investigated, together with the outcomes and the toxicity observed. RESULTS: SBRT has proven to maintain an excellent local control. The analysis showed the tumor size and the histology as determinant factors for the response to treatment. CONCLUSION: According to the published evidence as well as our own experience, SBRT is a safe and feasible approach for early NSCLC. Its results may be comparable with surgery treatment.
INTRODUCTION: Lung cancer is the most frequent neoplasm in humans. Surgery is considered the best therapeutic approach for stage I non-small lung cell cancer (NSCLC). However, a remarkable amount of patients are considered as inoperable. Stereotactic body radiotherapy (SBRT) has risen as an option for those patients, rendering excellent results in quality of life and survival. MATERIALS AND METHODS: We analyzed clinical studies published between 2002 and 2015 which included SBRT as a treatment modality. Our own clinical series was analyzed as well. The patterns of failure following SBRT were investigated, together with the outcomes and the toxicity observed. RESULTS: SBRT has proven to maintain an excellent local control. The analysis showed the tumor size and the histology as determinant factors for the response to treatment. CONCLUSION: According to the published evidence as well as our own experience, SBRT is a safe and feasible approach for early NSCLC. Its results may be comparable with surgery treatment.
Authors: Ronald C McGarry; Lech Papiez; Mark Williams; Tia Whitford; Robert D Timmerman Journal: Int J Radiat Oncol Biol Phys Date: 2005-08-22 Impact factor: 7.038
Authors: Bryan P Rowe; Daniel J Boffa; Lynn D Wilson; Anthony W Kim; Frank C Detterbeck; Roy H Decker Journal: J Thorac Oncol Date: 2012-09 Impact factor: 15.609
Authors: Inga S Grills; Victor S Mangona; Robert Welsh; Gary Chmielewski; Erika McInerney; Shannon Martin; Jennifer Wloch; Hong Ye; Larry L Kestin Journal: J Clin Oncol Date: 2010-01-11 Impact factor: 44.544
Authors: Sinisa Stanic; Rebecca Paulus; Robert D Timmerman; Jeff M Michalski; Robert B Barriger; Andrea Bezjak; Gregory M M Videtic; Jeffrey Bradley Journal: Int J Radiat Oncol Biol Phys Date: 2014-04-01 Impact factor: 7.038
Authors: R E Vadalà; A Santacaterina; A Sindoni; A Platania; A Arcudi; G Ferini; M M Mazzei; D Marletta; C Rifatto; E V I Risoleti; C Severo; A Pontoriero; G Iatì; S Pergolizzi Journal: Clin Transl Oncol Date: 2016-09-29 Impact factor: 3.405
Authors: Roman O Kowalchuk; Michael R Waters; Sujith Baliga; K Martin Richardson; Kelly M Spencer; James M Larner; Charles R Kersh Journal: Transl Lung Cancer Res Date: 2020-10
Authors: Moataz Reda; Worapol Ngamcherdtrakul; Shenda Gu; Daniel S Bejan; Natnaree Siriwon; Joe W Gray; Wassana Yantasee Journal: Cancer Lett Date: 2019-09-26 Impact factor: 8.679